The Worldwide Market for Vaccines to reach US$50.7 billion in 2013, forecasts New Report

May 8, 2009 - PRLog -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report offering detailed insights into the worldwide vaccines market.

“Pharmaceutical ScientiaVision Product Pinpoint: The New Vaccines”, available at http://tinyurl.com/qregdx reports that the vaccines approved in the last five years have created entirely new markets addressing patients of all ages. Merck's RotaTeq and GlaxoSmithKline's Rotarix rotavirus vaccines are intended for infants; Merck's Gardasil and GlaxoSmithKline's Cervarix human papillomavirus (HPV) vaccines are intended for female patients aged 9 to 26; GlaxoSmithKline's Twinrix provides protection against both hepatitis A and hepatitis B for patients aged 18 and over, and Merck's Zostavax prevents herpes zoster (shingles) in patients aged 60 and over.  

Vaccines in new therapeutic areas have expanded the target population for vaccines. Coupled with increased emphasis on immunization worldwide, expensive cancer vaccines on the horizon, and increased immunization in emerging markets, the vaccines market is exploding fast.  New blockbuster vaccines have changed the face of the market. Leading products and product lines in 2008 totaled US$10.0 billion (€6.9 billion) and included the following:

•   Prevnar (Wyeth):  2008 sales of US$2.7 billion (€1.9 billion);
•   Gardasil (Merck):  2008 sales of US$1.4 billion (€959 million), sales estimated at US$2.3 billion (€1.6 billion) when counting Gardasil sales by Merck, Sanofi Pasteur MSD, and CSL;
•   ProQuad/M-M-R II/Varivax (Merck):  2008 sales of US$1.3 billion (€867 million);
•   Infanrix/Pediarix (GlaxoSmithKline):  2008 sales of US$1.3 billion (€859 million);
•   Polio/Whooping Cough/Hib Vaccines (Sanofi Pasteur):  2008 sales of US$1.1 billion (€768 million); and
•   Influenza Vaccines (Sanofi Pasteur):  2008 sales of US$1.1 billion (€736 million).

The worldwide market for vaccines has more than doubled in three years, from US$11.6 billion (€9.4 billion) in 2005 to US$25.2 billion (€16.5 billion) in 2008, having grown at a compound annual rate of 31.8% (27.6% for Euros).  The market has primarily been driven by the billion-dollar products Prevnar; Gardasil; Merck's ProQuad/M-M-R II/Varivax line; Infanrx and Pediarix; GlaxoSmithKline's hepatitis line; Sanofi Pasteur's line of polio/whooping cough/Hib vaccines; and Sanofi Pasteur's line of influenza vaccines. The report projects that sales will more than double again to US$50.7 billion (€34.7 billion) in 2013, reflecting compound annual growth of 21.7% (19.2% for Euros).  

“ScientiaVision Product Pinpoint: The New Vaccines” is available from Piribo. For more information, visit:
http://www.piribo.com/publications/therapeutic/vaccines/n...

Piribo product ID: STV00001

# # #

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 12,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.